Allinaire Therapeutics aims to develop novel therapeutics for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases. The technology is based on the discovery by scientific founders Irina Petrache, MD, and Matthias Clauss, PhD of a novel therapeutic target that plays a central role in the development and progression of lung disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/27/17 | undisclosed |
BioCrossroads BioMotiv Innovate Indiana Fund | undisclosed |
